HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
hookipa pharma宣佈HB-200與Pembrolizumab結合用於HPV16+頭頸癌的二期結果。
- Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
- In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%
- Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of care
- Company will host a conference call at 4:15 p.m. ET today
- 採用HB-200加帕博利珠單抗治療的35名可評估的頭頸部一線患者中觀察到鼓舞人心的臨床活性，響應程度加深
- 在17名可評估的PD-L1聯合評分（CPS）爲20或更高的患者中，這是公司選擇的註冊主要試驗人群，數據顯示確認的ORR爲53％，CR率爲18％，DCR爲82％
- CPS爲20或更高的亞組的初步無進展生存期（PFS）爲16.3個月，初步總體生存率（OS）爲9個月時爲88％，與目前的標準板相比有優勢
- 公司將於今天下午4:15在東部時間舉行電話會議
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。